Drug Database
Back to search

Netherlands· NL-8e3b35b53806

Iclusig 5 mg harde capsules

A ponatinib product containing ponatinibhydrochloride, registered in Netherlands by Incyte Biosciences Distribution B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L01EA05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedIclusig 5 mg harde capsulesATCL01EA05REGISTER NO.NL-8e3b35b53806PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ponatinibhydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ponatinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EA05 (ponatinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search ponatinib products by name

Ponatinib · ATC L01EA05

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ponatinib costs, country by country.

Normalised to the WHO defined daily dose (45 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ponatinib · price per daily dose (45 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$296.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
PONATINIBHYDROCHLORIDE
Manufacturer
Incyte Biosciences Distribution B.V.
Country
Netherlands (NL)
ATC code
L01EA05
ATC class
Ponatinib
Defined daily dose
45 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/13/839

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

500 interactions on record for ponatinib.

Graded by severity as the source publishes them — 166 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ponatinib against other medicinesHow interaction checks work

Ponatinib · interactions on record

500 records

  • 166 severe
  • 303 moderate
  • 31 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ponatinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ponatinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Iclusig
  • Liechtenstein · Iclusig
  • Norway · Iclusig

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ea27b696-eedd-4cab-85da-d7a8999c46d7
GET /v1/drugs/ea27b696-eedd-4cab-85da-d7a8999c46d7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ponatinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp135813",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE (E 464)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "PONATINIBHYDROCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2013/07/01",
  "procedure_number": "EMEA/H/C/002695",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/839",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about ponatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console